Menu Search
Equities

IRadimed Corp

IRMD:NMQ

IRadimed Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)56.95
  • Today's Change-0.40 / -0.70%
  • Shares traded30.38k
  • 1 Year change+43.92%
  • Beta0.8374
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year IRadimed Corp grew revenues 23.00% from 53.30m to 65.56m while net income improved 34.02% from 12.83m to 17.19m.
Gross margin77.14%
Net profit margin26.12%
Operating margin29.91%
Return on assets20.51%
Return on equity23.58%
Return on investment22.48%
More ▼

Cash flow in USDView more

In 2023, cash reserves at IRadimed Corp fell by 8.20m. However, the company earned 13.47m from its operations for a Cash Flow Margin of 20.54%. In addition the company used 8.01m on investing activities and also paid 13.66m in financing cash flows.
Cash flow per share1.53
Price/Cash flow per share37.36
Book value per share6.59
Tangible book value per share6.36
More ▼

Balance sheet in USDView more

IRadimed Corp has little financial risk as the capital structure does not rely on leverage.
Current ratio9.21
Quick ratio7.82
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 33.11%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)63.22%
EPS growth(5 years)21.02
EPS (TTM) vs
TTM 1 year ago		13.62
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.